Spots Global Cancer Trial Database for acute myeloid leukemia, in relapse
Every month we try and update this database with for acute myeloid leukemia, in relapse cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment | NCT04321161 | Acute Myeloid L... | Bicanorm | 18 Years - | University of Freiburg | |
| A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | NCT06017258 | Refractory Acut... Relapsed Acute ... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CD371-YSNVZ-IL1... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML | NCT03690154 | Advanced Cancer Solid Tumors Acute Myeloid L... Acute Myeloid L... | FN-1501 | 18 Years - | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT04898894 | Acute Leukemia ... Acute Myeloid L... Refractory Acut... Refractory Acut... | Venetoclax Selinexor Cytarabine Fludarabine Filgrastim Methotrexate methotrexate/hy... | 2 Years - 30 Years | St. Jude Children's Research Hospital | |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | NCT05546580 | Acute Myeloid L... Acute Myeloid L... | Iadademstat Gilteritinib Or... | 18 Years - | Oryzon Genomics S.A. | |
| Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia | NCT02353143 | Recurrent Adult... Acute Myeloid L... | MEN1112 | 18 Years - | Menarini Group | |
| High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML | NCT02768792 | Acute Myeloid L... | pembrolizumab, | 18 Years - 70 Years | UNC Lineberger Comprehensive Cancer Center | |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | NCT05546580 | Acute Myeloid L... Acute Myeloid L... | Iadademstat Gilteritinib Or... | 18 Years - | Oryzon Genomics S.A. | |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06128044 | Acute Myeloid L... Acute Myeloid L... | CB-012 | 18 Years - | Caribou Biosciences, Inc. | |
| PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT02438761 | Therapy-related... Acute Myeloid L... de Novo Acute M... | PF-05212384 | 18 Years - | Institut Curie | |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06128044 | Acute Myeloid L... Acute Myeloid L... | CB-012 | 18 Years - | Caribou Biosciences, Inc. | |
| Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia | NCT04867928 | Acute Myeloid L... Acute Myeloid L... NPM1 Mutation | Venetoclax+azac... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT05854966 | Acute Myeloid L... Acute Myeloid L... Granulocytic Sa... | CPI 613 Metformin Blood draws Bone marrow bio... | 18 Years - | Wake Forest University Health Sciences | |
| Lentivirally Redirected CD123 Autologous T Cells in AML | NCT03766126 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CART123 cells; ... | 18 Years - | University of Pennsylvania | |
| PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT02438761 | Therapy-related... Acute Myeloid L... de Novo Acute M... | PF-05212384 | 18 Years - | Institut Curie | |
| Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 | NCT05949125 | Acute Myeloid L... Acute Myeloid L... | Cyclophosphamid... Fludarabine (No... R-TM123 Allo-RevCAR01-T | 18 Years - | AvenCell Europe GmbH | |
| CD123 Redirected T Cells for AML in Pediatric Subjects | NCT04678336 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CART123 cells; ... | 1 Year - 29 Years | University of Pennsylvania | |
| KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | NCT04914845 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | KPT-9274 | 18 Years - | University of Colorado, Denver | |
| Venetoclax to Augment Epigenetic Modification and Chemotherapy | NCT05317403 | Acute Myeloid L... Acute Myeloid L... | Venetoclax Azacitadine Vorinostat Cytarabine Fludarabine Filgrastim | 1 Year - 25 Years | Medical College of Wisconsin | |
| A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia | NCT03053206 | Acute Myeloid L... | ADE Protocol | - 18 Years | All India Institute of Medical Sciences, New Delhi | |
| Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT04898894 | Acute Leukemia ... Acute Myeloid L... Refractory Acut... Refractory Acut... | Venetoclax Selinexor Cytarabine Fludarabine Filgrastim Methotrexate methotrexate/hy... | 2 Years - 30 Years | St. Jude Children's Research Hospital | |
| A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02204085 | Acute Myeloid L... Recurrent Adult... | GO-203-2c GO-203-2c + Dec... | 18 Years - | Beth Israel Deaconess Medical Center | |
| An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia | NCT06281847 | Acute Myeloid L... Acute Myeloid L... | CCTx-001 | 18 Years - | Advesya SAS | |
| High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML | NCT02768792 | Acute Myeloid L... | pembrolizumab, | 18 Years - 70 Years | UNC Lineberger Comprehensive Cancer Center | |
| CD123 Redirected T Cells for AML in Pediatric Subjects | NCT04678336 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CART123 cells; ... | 1 Year - 29 Years | University of Pennsylvania | |
| Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 | NCT05949125 | Acute Myeloid L... Acute Myeloid L... | Cyclophosphamid... Fludarabine (No... R-TM123 Allo-RevCAR01-T | 18 Years - | AvenCell Europe GmbH | |
| Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT05597306 | Acute Myeloid L... Refractory Acut... Acute Myeloid L... | Bomedemstat Venetoclax | 18 Years - | University of Miami | |
| Off-the-shelf CD123 CAR-NK for R/R AML | NCT06201247 | Acute Myeloid L... Acute Myeloid L... | JD123 injection | 18 Years - | Peking University People's Hospital | |
| A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML | NCT03690154 | Advanced Cancer Solid Tumors Acute Myeloid L... Acute Myeloid L... | FN-1501 | 18 Years - | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | NCT05190471 | Acute Myeloid L... Acute Myeloid L... | BP1002; Liposom... Decitabine (in ... | 18 Years - | Bio-Path Holdings, Inc. | |
| Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia | NCT03957915 | Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Mixed Phenotype... | INA03 administr... | 18 Years - | Institut Paoli-Calmettes | |
| Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) | NCT05587088 | Neoplasm, Stoma... Gastric Neoplas... Pancreatic Neop... Colorectal Neop... Acute Leukemia Acute Leukemia ... Acute Leukemia ... Acute Myeloid L... Acute Myeloid L... | Petiveria Allia... Placebo | 18 Years - 99 Years | Hospital Universitario San Ignacio | |
| A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia | NCT03053206 | Acute Myeloid L... | ADE Protocol | - 18 Years | All India Institute of Medical Sciences, New Delhi | |
| AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT05211570 | Acute Myeloid L... Acute Myeloid L... Myelodysplastic... | AB8939 Azacitidine | 18 Years - | AB Science | |
| Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways | NCT05124288 | Acute Myeloid L... | Observations on... | 18 Years - | IRCCS San Raffaele | |
| A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02204085 | Acute Myeloid L... Recurrent Adult... | GO-203-2c GO-203-2c + Dec... | 18 Years - | Beth Israel Deaconess Medical Center | |
| Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 | NCT05949125 | Acute Myeloid L... Acute Myeloid L... | Cyclophosphamid... Fludarabine (No... R-TM123 Allo-RevCAR01-T | 18 Years - | AvenCell Europe GmbH | |
| Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT04716452 | Acute Myeloid L... Acute Myeloid L... | Ceramide NanoLi... | 18 Years - | Keystone Nano, Inc | |
| Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT04402541 | Acute Myeloid L... Myelodysplastic... | CB-5339 | 18 Years - | Cleave Therapeutics, Inc. | |
| CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06128044 | Acute Myeloid L... Acute Myeloid L... | CB-012 | 18 Years - | Caribou Biosciences, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
